CHO Pharma Inc. (6586.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan
CHO Pharma Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 3.58 m TWD | 1.43 m TWD |
| Gross profit | 1.71 m TWD | 1.07 m TWD |
| Operating income | -249.29 m TWD | -325.84 m TWD |
| EBIT | -211.55 m TWD | -289.60 m TWD |
| Net income | -212.23 m TWD | -290.01 m TWD |
| Diluted EPS – continuing operations | -0.99 TWD | -1.36 TWD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CHO Pharma Inc.
CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies. The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetter or ADC. In addition, the company develops CHO-H01, which is in Phase I/IIa clinical trials for the treatment of refractory non-Hodgkin lymphoma; CHO-A04, a humanized monoclonal antibody, which is in phase I clinical trials to treat various tumor and cancer stem cells; and CHO-V08 vaccines for the treatment of klebsiella pneumonia. Further, it develops CHO-H02 that is in preclinical stage to target solid tumors, including breast, bladder, pancreatic, ovarian, and gastric cancers; and CHO-H03, an antibody drug that is in pre-clinical development stage indicated for inflammatory conditions in autoimmune diseases such as rheumatoid arthritis, ulcerative colitis and Crohn's disease. CHO Pharma, Inc. was founded in 2012 and is based in Taipei City, Taiwan.
More stocks
- Hubei Xiangyuan New Material Technology Inc. (300980.SZ)
- Zhejiang Yatai Pharmaceutical Co Ltd (002370.SZ)
- Atria Oyj (ATRAV.HE)
- Heren Health Co Ltd (300550.SZ)
- CRESCENT BIOPHARMA, INC. (CBIO)
- Zhejiang Zhengte Co Ltd (001238.SZ)
- First Farmers Financial Corp (FFMR)
- Mears Group PLC (MER.L)
- Anhui Jinchun Nonwoven Co Ltd (300877.SZ)
- IVU Traffic Technologies (IVU.DE)
- Jinxiandai Information Industry Co (300830.SZ)
- Hunan Airbluer Environmental Protection Technology Co. Ltd. (301259.SZ)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.